Previous 10 | Next 10 |
2024-03-17 19:46:57 ET More on the markets SPTM: A Solid But Unnecessary Total Market ETF S&P 500: Time To Hedge, Here's How How the Magnificent 7 valuations stack up against bubbles of yore S&P 500 notches two-week losing streak ahead of key Fed rate...
2024-03-02 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-21 16:42:49 ET More on Glaukos Glaukos: Remains A Hold Due To High Valuation And Negative Profitability Glaukos Q4 2023 Earnings Preview Sight Sciences slips despite Medicare decision on glaucoma procedure (update) Seeking Alpha’s Quant Rating ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highl...
Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...
2024-02-20 17:20:57 ET More on Glaukos Glaukos: Remains A Hold Due To High Valuation And Negative Profitability Sight Sciences slips despite Medicare decision on glaucoma procedure (update) Sight Sciences climbs after update on Medicare coverage for glaucoma procedur...
2024-02-16 07:30:02 ET Truist Financial analyst issues BUY recommendation for GKOS on February 16, 2024 07:00AM ET. The previous analyst recommendation was Buy. GKOS was trading at $96.11 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...
2024-02-09 20:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full...
2024-01-09 09:50:03 ET More on Glaukos Glaukos: Remains A Hold Due To High Valuation And Negative Profitability Glaukos Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Glaukos For further details see: Glaukos says 2023 revenue to b...
News, Short Squeeze, Breakout and More Instantly...
2024-05-06 04:00:04 ET Michael Sarcone from Jefferies issued a price target of $125.00 for GKOS on 2024-05-06 01:02:00. The adjusted price target was set to $125.00. At the time of the announcement, GKOS was trading at $106.51. The overall price target consensus is at $7...
Thursday, Glaukos Corporation (NYSE:GKOS) reported a first-quarter adjusted EPS loss of $(0.70), up from $(0.59) a year ago, missing the&...
U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday. Shares of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) rose sh...